GLP1R and obesity due to melanocortin 4 receptor deficiency: Although the cardiovascular benefits of using GLP-1 RAs for diabetic patients have been well-documented [9], there was previously a paucity of evidence for using these agents for cardiovascular risk reduction in nondiabetic overweight/obesity.